PHOTODYNAMIC THERAPY with VERTEPORFIN PLUS INTRAVITREAL BEVACIZUMAB for CIRCUMSCRIBED CHOROIDAL HEMANGIOMA: 4 YEARS of FOLLOW-UP

Andres F. Lasave, Martin A. Serrano, J. Fernando Arevalo

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Purpose:To report the anatomical and functional response of combined photodynamic therapy and intravitreal injection of bevacizumab in a patient with symptomatic circumscribed choroidal hemangioma.Methods:The patient received a single-session full-fluence photodynamic therapy immediately followed by an intravitreal injection of bevacizumab (1.25 mg/0.05 mL).Results:One week after combined therapy, an improvement of best-corrected visual acuity from count fingers to 20/60 and a significant decrease in subretinal fluid were noted. One month later, we observed decreased leakage on fluorescein angiography in all phases of the study. Three months after treatment, the best-corrected visual acuity improved to 20/25 and spectral domain optical coherence tomography scans showed return to normal foveal architecture with no subretinal fluid and completely flat tumor. These findings were maintained during 4 years of follow-up.Conclusion:Combination therapy was associated with a rapid and persistent resolution of subretinal fluid, improvement of best-corrected visual acuity, and visual stability at 4 years of follow-up.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalRetinal Cases and Brief Reports
Volume14
Issue number2
DOIs
StatePublished - 2020

Keywords

  • bevacizumab
  • circumscribed choroidal hemangioma
  • intravitreal anti-vascular endothelial growth factor
  • photodynamic therapy

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'PHOTODYNAMIC THERAPY with VERTEPORFIN PLUS INTRAVITREAL BEVACIZUMAB for CIRCUMSCRIBED CHOROIDAL HEMANGIOMA: 4 YEARS of FOLLOW-UP'. Together they form a unique fingerprint.

Cite this